Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study
Obesity · 2026-02 · 34 (2) · 482-490
DOI: 10.1002/oby.70076 ↗At a glance
Kohortenstudie in Obesity, published online on 2025-11-21. Written by G Caleb Alexander and 5 co-authors. Institution: Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Weight Loss, Weight Gain, Hypoglycemic Agents. Cited 3 times so far (Crossref); 35 references. The full text is freely available in PubMed Central. Funded by: NIA NIH HHS, National Institute on Aging.
Abstract (original language)
Objective
This study aimed to quantify the effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1s) on weight loss and weight gain following GLP‐1 discontinuation.
Methods
This retrospective cohort study using electronic health records from TriNetX included individuals age 18 years or older with various lengths of continuous GLP‐1 use between September 2014 and November 2023. Applying an intention‐to‐treat framework, we used linear mixed effects models and propensity score adjustment to model changes in BMI after GLP‐1 discontinuation while accounting for correlated within‐person observations and potential confounders.
Results
A total of 78,076 (19.7%) individuals used GLP‐1s continuously for 3 months, 23,861 (6.0%) for 6 months, and 12,642 (3.2%) for 9 months. The median BMI prior to initiation was 36.38 (IQR 36.30–36.46), which declined by 2.15% (IQR 2.10%–2.21%) to 35.81 (IQR 35.7–35.92) among individuals with 3 months of continuous GLP‐1 use. Median BMI declines were greater among individuals with 6 months (4.38%, IQR 4.27%–4.48%) and 9 months (5.56%, IQR 5.34%–5.78%) of continuous use. On average, weight loss among discontinuers at months 3, 6, and 9 slowed in comparison to their counterparts.
Conclusions
Among this real‐world sample, GLP‐1 use was associated with more modest weight loss than has been demonstrated in randomized controlled trials.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.
- Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
ORCID profiles: G Caleb Alexander
Funding
- NIA NIH HHS
- National Institute on Aging
Cite
APA
Alexander, G. C., Xu, Y., Xiao, X., Lewis, S. V., Zeger, S., & Mehta, H. B. (2026). Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study. Obesity, 34(2), 482-490. https://doi.org/10.1002/oby.70076
Vancouver
Alexander GC, Xu Y, Xiao X, Lewis SV, Zeger S, Mehta HB. Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study. Obesity. 2026;34(2):482-490. doi:10.1002/oby.70076
BibTeX
@article{Alexander2026,
author = {Alexander, G Caleb and Xu, Yizhen and Xiao, Xuya and Lewis, Sydney V and Zeger, Scott and Mehta, Hemalkumar B},
title = {Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study},
journal = {Obesity},
year = {2026},
volume = {34},
number = {2},
pages = {482--490},
doi = {10.1002/oby.70076}
}
EUVIMED